https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43546 Wed 21 Sep 2022 16:26:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:18510 Wed 11 Apr 2018 14:04:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39616 Dw,w), dose to water in medium (Dw,m), and dose to medium in medium (Dm,m). This was done based on a review of historical frameworks, existing literature and standards, clinical issues in the context of clinical trials, and the trajectory of radiation dose calculations. Based on these factors, recommendations were developed. Results: No framework was found to be ideal or perfect given the history, complexity, and current status of radiation therapy. Nevertheless, based on the evidence available, the GHG established a recommendation preferring dose to medium in medium (Dm,m). Conclusions: Dose to medium in medium (Dm,m) is the preferred dose calculation and reporting framework. If an institution’s planning system can only calculate dose to water in water (Dw,w), this is acceptable.]]> Wed 10 Aug 2022 11:54:01 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30211 Wed 09 Feb 2022 15:53:54 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45588 Wed 02 Nov 2022 10:40:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51626 Tue 12 Sep 2023 15:40:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51315 Thu 31 Aug 2023 14:30:36 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46465 n=388) and CHHiP (n=241) trials onto the same exemplar and repeating the tests on each of these data sets, and on all three datasets combined. Results: Voxel-based Cox regression and permutation dose difference testing revealed regions where increased dose was correlated with gastrointestinal toxicity. Grade=2 RB was associated with posteriorly extended lateral beams that manifested high doses (> 55 Gy) in a small rectal volume adjacent to the clinical target volume. A correlation was found between grade=2 tenesmus and increased low-intermediate dose (~25 Gy) at the posterior beam region, including the posterior rectum and perirectal fat space (PRFS). Conclusions: The serial response of the rectum with respect to RB has been demonstrated in patients with posteriorly extended lateral beams. Similarly, the parallel response of the PRFS with respect to tenesmus has been demonstrated in patients treated with the posterior beam.]]> Thu 24 Nov 2022 15:46:42 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34638 Patient: A patient with prostate adenocarcinoma undergoing SBRT with 36.25 Gy, delivered in 5 fractions was enrolled in the study. 6DoF KIM technology: 2D positions of three implanted gold markers in each of the kV images (125 kV, 10 mA at 11 Hz) were acquired continuously during treatment. The 2D → 3D target position estimation was based on a probability distribution function. The 3D → 6DoF target rotation was calculated using an iterative closest point algorithm. The accuracy and precision of the KIM method was measured by comparing the real-time results with kV-MV triangulation. Results: Of the five treatment fractions, KIM was utilised successfully in four fractions. The intrafraction prostate motion resulted in three couch shifts in two fractions when the prostate motion exceeded the pre-set action threshold of 2 mm for more than 5 s. KIM translational accuracy and precision were 0.3 ± 0.6 mm, −0.2 ± 0.3 mm and 0.2 ± 0.7 mm in the Left-Right (LR), Superior-Inferior (SI) and Anterior-Posterior (AP) directions, respectively. The KIM rotational accuracy and precision were 0.8° ± 2.0°, −0.5° ± 3.3° and 0.3° ± 1.6° in the roll, pitch and yaw directions, respectively. Conclusion: This treatment represents, to the best of our knowledge, the first time a cancer patient’s tumour position and rotation have been monitored in real-time during treatment. The 6 DoF KIM system has sub-millimetre accuracy and precision in all three translational axes, and less than 1° accuracy and 4° precision in all three rotational axes.]]> Thu 24 Mar 2022 11:35:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42975 Thu 22 Jun 2023 08:51:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51856 Thu 21 Sep 2023 09:41:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51846 Thu 21 Sep 2023 09:27:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40147 in situ (DCIS) of the breast. Materials and methods: Baseline and 3-year cosmesis were assessed using the European Organization for Research and Treatment of Cancer (EORTC) Cosmetic Rating System and digital images in a randomised trial of non-low risk DCIS treated with postoperative WBI +/− TBB. Baseline cosmesis was assessed for four geographic clusters of treating centres. Cosmetic failure was a global score of fair or poor. Cosmetic deterioration was a score change from excellent or good at baseline to fair or poor at three years. Odds ratios for cosmetic deterioration by WBI dose-fractionation and TBB use were calculated for both scoring systems. Results: 1608 women were enrolled from 11 countries between 2007 and 2014. 85–90% had excellent or good baseline cosmesis independent of geography or assessment method. TBB (16 Gy in 8 fractions) was associated with a >2-fold risk of cosmetic deterioration (p < 0.001). Hypofractionated WBI (42.5 Gy in 16 fractions) achieved statistically similar 3-year cosmesis compared to conventional WBI (50 Gy in 25 fractions) (p ≥ 0.18). The adverse impact of a TBB was not significantly associated with WBI fractionation (interaction p ≥ 0.30). Conclusions: Cosmetic failure from BCS was similar across international jurisdictions. A TBB of 16 Gy increased the rate of cosmetic deterioration. Hypofractionated WBI achieved similar 3-year cosmesis as conventional WBI in women treated with BCS for DCIS.]]> Thu 11 Aug 2022 14:56:25 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52206 5% increase in spinal cord dose relative to the original plans. Six plans (from four institutions) passed despite a >10% increase. Conclusions: This novel audit concept evolves beyond testing an institution’s ability to deliver a single test case, to increasing the number of errors caught by institutions themselves, thus increasing quality of radiation therapy and impacting every patient treated. Administered remotely this audit also provides advantages in cost, environmental impact, and logistics.]]> Thu 05 Oct 2023 10:15:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7230 Sat 24 Mar 2018 08:40:27 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8029 Sat 24 Mar 2018 08:36:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:8027 Sat 24 Mar 2018 08:36:47 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:7330 Sat 24 Mar 2018 08:35:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:1464 Sat 24 Mar 2018 08:28:05 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12469 Sat 24 Mar 2018 08:16:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12323 Sat 24 Mar 2018 08:11:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12305 Sat 24 Mar 2018 08:11:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:21390 p< 0.001) in urinary dysfunction were measured using the EORTC PR25 instrument at 18 and 36 months. Conclusion: Adjuvant androgen suppression, bisphosphonates and increasing EBRT dose did not increase rectal or urinary dysfunction in this trial. However dose escalation using HDRB increased urinary dysfunction.]]> Sat 24 Mar 2018 08:05:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:275 Sat 24 Mar 2018 07:43:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22823 Sat 24 Mar 2018 07:16:10 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22835 1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions: The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.]]> Sat 24 Mar 2018 07:16:08 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:22558 Sat 24 Mar 2018 07:14:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24640 Breast_Shape =0.99±0.01, were achieved. Decreasing image resolution decreased contouring conformity.]]> Sat 24 Mar 2018 07:11:53 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52848 Mon 30 Oct 2023 09:53:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44898 Mon 24 Oct 2022 16:10:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49488 Fri 19 May 2023 09:42:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33737 w) MR images of the pelvis. Materials and methods: This study developed a generalized dual model HU conversion method to convert standard T2_w MR image intensity values to synthetic HU values, separately inside and outside of atlas-segmented bone volume contour. The method was developed and evaluated with 20 and 35 prostate cancer patients, respectively. MR images with scanning sequences in clinical use were acquired with four different MR scanners of three vendors. Results: For the generated synthetic CT (sCT) images of the 35 prostate patients, the mean (and maximal) HU differences in soft and bony tissue volumes were 16 ± 6 HUs (34 HUs) and −46 ± 56 HUs (181 HUs), respectively, against the true CT images. The average of the PTV mean dose difference in sCTs compared to those in true CTs was −0.6 ± 0.4% (−1.3%). Conclusions: The study provides a generalized method for sCT creation from standard T2_w images of the pelvis. The method produced clinically acceptable dose calculation results for all the included scanners and MR sequences.]]> Fri 14 Dec 2018 14:49:01 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33735 Fri 14 Dec 2018 14:41:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38429 p = 0.04, ROC AUC 0.90) and standard deviation (SD) (p = 0.02, ROC AUC 0.90), week 2 skewness (p = 0.02, ROC AUC 0.91) and SD (p = 0.01, ROC AUC 0.94), week 4 kurtosis (p = 0.01, AUC 0.92) and SD (p = 0.01, ROC AUC 0.96). Changes in minimum ADC between baseline and week 2 (p = 0.02, ROC AUC 0.94) and baseline and week 4 (p = 0.02, ROC AUC 0.94) were prognostic for local recurrence. For prediction of any recurrence, ADC minimum (p = 0.02, ROC AUC 0.87) and SD (p = 0.01, ROC AUC 0.85) at baseline, and ADC maximum (p = 0.03, ROC AUC 0.77) and SD (p = 0.02, ROC AUC 0.81) at week 4 were significant. On LASSO logistic regression, ADC minimum and SD at baseline were retained for any recurrence. The only significant finding for DCE-MRI was a correlation of k-trans min at the second follow-up with local recurrence (p = 0.05, AUC 0.84). Conclusion: Several ADC parameters at various time points correlate with recurrence suggesting DW-MRI is a potential biomarker for SCCAC.]]> Fri 10 Sep 2021 12:16:47 AEST ]]>